Trial of Intracycle Sequential Ofatumumab and Lenalidomide for the Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab

This study has been completed.
Sponsor:
Collaborators:
GlaxoSmithKline
Celgene Corporation
Information provided by (Responsible Party):
Luciano J. Costa, Medical University of South Carolina
ClinicalTrials.gov Identifier:
NCT01123356
First received: May 4, 2010
Last updated: June 18, 2013
Last verified: July 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2013
  Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)